Novan Welcomes Key Opinion Leaders to New Advisory Council
04 avr. 2017 09h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., April 04, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has formed an Advisory Council comprised of key opinion...
Novan Provides Update on SB204 Development Program
06 mars 2017 06h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., March 06, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that, after further analysis of the results from the NI-AC301 and NI-AC302...
Novan Announces SB204 Program Update Conference Call and Webcast
03 mars 2017 16h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., March 03, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Monday, Mar. 6, at 8 a.m....
Melinta Therapeutics Announces FDA Acceptance of Investigational New Drug Application for Topical Radezolid
28 févr. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today the U.S. Food...
Dermira to Report Fourth Quarter and Full Year 2016 Financial Results
22 févr. 2017 16h36 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Novan Licenses SB204 to Sato for Acne in Japan
17 janv. 2017 09h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has entered into an exclusive license agreement with Sato...
Novan to Present Data from SB204 Phase 2b Trial at Fall Clinical Dermatology Conference
18 oct. 2016 09h05 HE
|
Novan, Inc.
DURHAM, N.C., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that results from the Company’s Phase 2b clinical trial to evaluate the efficacy...
Dermira Announces Proposed Public Offering of Common Stock
07 juin 2016 16h06 HE
|
Dermira, Inc.
MENLO PARK, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting
11 mai 2016 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports First Quarter 2016 Financial Results and Provides Corporate Update
10 mai 2016 06h30 HE
|
Dermira, Inc.
- Positive Topline Results for DRM01 Phase 2b Acne Trial Reported; Phase 3 Program Planning Underway - Announcement of Topline Results for DRM04 Phase 3 Hyperhidrosis Pivotal Trials Expected in...